经皮骨强化术治疗非小细胞肺癌溶骨性胸骨转移瘤
Percutaneous bone augmentation enhancement treatment for osteolytic sternal metastases of non-small cell lung cancer
李传海 1贺呈祥 1刘训伟 2吕昌鹏 3张梅1
作者信息
- 1. 中国人民解放军联勤保障部队第960医院胸外科 山东 济南 250031
- 2. 中国人民解放军联勤保障部队第960医院南院肿瘤科 山东济南 250031
- 3. 山东省郓城县诚信医院胸外科 山东 菏泽 274700
- 折叠
摘要
目的 探讨经皮骨强化术(PBA)治疗非小细胞肺癌溶骨性胸骨转移瘤的疗效.方法 选取 10 例经病理证实的非小细胞肺癌溶骨性胸骨转移瘤行PBA的资料,回顾性分析手术治疗方法,采用术前、术后视觉模拟评分(VAS)、KPS评分评估临床疗效.采用 SPSS 19.0 统计学软件单因素方差分析,对所得数据进行统计学分析,以 P<0.05 为差异有统计学意义.结果 10 例患者均顺利完成手术,术后 1 周,VAS评分由术前 8.60±0.97 降至术后 2.70±0.67;KPS评分由术前 31.00±9.94 升至术后 77.00±10.59,治疗前后两者差异均有统计学意义(P<0.05).结论 PBA治疗非小细胞肺癌溶骨性胸骨转移瘤创伤小且安全,可获得良好的止痛效果,有效提高患者的生活质量.
Abstract
Objective To investigate the efficacy of percutaneous bone augmentation in the treatment of osteolytic sternal me-tastases of non-small cell lung cancer.Methods The data of 10 patients with pathology confirmed osteolytic sterna metastases of non-small cell lung cancer underwent percutaneous bone augmentation treatment were collected.The surgical treatment meth-ods were retrospectively analyzed.The clinical efficacy was evaluated by visual analogue scale(VAS)and karnofsky performance status(KPS)before and after operation.SPSS 19.0 statistical software was used to analyze the data by one-way ANOVA.P<0.05 indicated that the difference was significant.Results All the 10 patients were completed the operation successfully.The VAS score decreased from 8.60±0.97 to 2.70±0.67 after operation,and KPS score decreased from 31.00±9.94 to 77.00±10.59 af-ter operation,and the difference was statistically significant(P<0.05).Conclusion Percutaneous bone augmentation in the treatment of non-small cell lung cancer with osteolytic metastases of sternum can obtain good analgesic effect,improve the behav-ior ability of patients,with less trauma and safety,which can significantly improve the quality of life of patients.
关键词
胸骨转移瘤/经皮骨强化术/肺癌/介入性,放射学Key words
Sternal metastases/Percutaneous bone augmentation/Lung cancer/Interventional radiology引用本文复制引用
出版年
2024
NETL
NSTL
万方数据